All In MedTech

Device Trial Radar · NCT07696754

Augmented-Reality ICG Fluorescence Second-Look for Residual Nodal Disease After Axillary Dissection in Breast Cancer

Prospective Evaluation of Augmented-Reality ICG Fluorescence Second-Look After Axillary Lymph Node Dissection in Breast Cancer

Last checked: Nov 19, 2026Latest source record: Nov 13, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

200

Planned (sponsor's estimate)

Start

Nov 2026

Primary completion

Oct 2029

Study completion Nov 2029

Sponsor

Lead sponsor
Ss. Cyril and Methodius University of SkopjeAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
University of Illinois at Urbana-Champaign
First posted
Jul 10, 2026

More device trials from this sponsor

Design

Study type
Interventional
Phase
Not applicable (typical for device studies)
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Diagnostic
FDA-regulated device
No
Who can join
Female only, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This prospective study will enroll up to 200 patients whose clinical team has already planned an axillary lymph node dissection for breast cancer. After the surgeon completes the planned dissection and declares that no further tissue was intended for removal, a wearable augmented-reality/virtual-reality (AR/VR) system will show indocyanine-green (ICG) near-infrared fluorescence during a brief second look at the exposed surgical field. The surgeon may remove an additional fluorescent focus only after inspection under normal light and only when removal is safe and clinically appropriate. Each additional specimen will be labeled separately and examined by pathology. The study measures the proportion of patients with an additional tumor-positive lymph node found at second look, whether such nodes change the pathological nodal category, operating time, and adverse events. The first 50 consecutive participants will form a planned descriptive device-feasibility analysis; all 200 participants will contribute to the full-cohort clinical analysis. The study does not assume that finding an additional node improves recurrence or survival.

Conditions

  • Breast Cancer
  • Breast Neoplasms
  • Sentinel Lymph Node
  • Lymphatic Metastasis

Interventions

  • Augmented-reality ICG fluorescence second-look imagingDevice

    A wearable augmented-reality system displaying combined color and near-infrared fluorescence, with a handheld laser/white-light illuminator, used to re-examine the axillary field for residual ICG-fluorescent tissue after the surgeon declares the dissection complete. Indocyanine green is administered intraoperatively per protocol.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Patient-level rate of clinically significant events (CSE)Time frame: From intraoperative second-look review to final histopathology (up to approximately 2 weeks after surgery)

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • University Clinic for Thoracic and Vascular Surgery, Faculty of Medicine, UKIM

    Skopje, North Macedonia · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.